All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On July 24, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to brexucabtagene autoleucel, formerly KTE-X19, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).1,2
Brexucabtagene autoleucel is a chimeric antigen receptor (CAR) T-cell therapy targeting the CD19 antigen on the surface of lymphoma cells. The FDA approval, that follows a priority review and FDA breakthrough therapy designation, was based on data from the ongoing ZUMA-2 trial in patients with R/R MCL who had previously received anthracycline- or bendamustine-containing chemotherapy, an anti-CD20 antibody therapy, and a Bruton tyrosine kinase inhibitor. Results demonstrated an objective response rate of 87% and a complete response rate of 62%.1,2
In the trial, among patients evaluable for safety (n = 82), 91% experienced cytokine release syndrome (CRS) including 18% with ≥ Grade 3 CRS, and 81% experienced neurologic events including 37% with ≥ Grade 3. Due to the risk of CRS and neurologic toxicities, brexucabtagene autoleucel is only available through a restricted program under a risk evaluation and mitigation strategy.1
A manufacturing success rate of 96% was reported in the ZUMA-2 trial, with a median manufacturing time of 15 days from leukapheresis to product delivery.
Dana-Farber/Brigham and Women's Cancer Center (DF/BWCC) will be a certified treatment center for the therapy.2
Brexucabtagene autoleucel is under review in the European Union, and it is under investigation in phase I/II trials involving patients with acute lymphoblastic leukemia (NCT02614066) and chronic lymphocytic leukemia (NCT03624036).1
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox